Immunic (IMUX) Net Cash Flow (2013 - 2026)
Immunic (IMUX) posted Net Cash Flow of $171.3 million for Q1 2026, up 990.86% sequentially from -$19.2 million in Q4 2025, and up 885.13% YoY from $17.4 million in Q1 2025.
Immunic (IMUX) Net Cash Flow (2013 - 2026) Analysis & Trends
Immunic has reported Net Cash Flow for 14 years, with the latest figure at $171.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 885.13% year-over-year to $171.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.8 million (up 308.72% YoY) and the FY2025 annual result came in at -$20.4 million, down 94.39% from the prior year.
- Net Cash Flow improved to $171.3 million in Q1 2026 per IMUX's latest filing, from -$19.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $171.3 million in Q1 2026 and troughed at -$22.9 million in Q4 2024.
- A 5-year average of $5.9 million and a median of -$14.1 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow slumped 257.84% in 2023, then jumped 885.13% in 2026.
- Over 5 years, Net Cash Flow stood at $31.3 million in 2022, then plunged by 143.4% to -$13.6 million in 2023, then plunged by 68.45% to -$22.9 million in 2024, then advanced by 15.97% to -$19.2 million in 2025, then soared by 990.86% to $171.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $171.3 million, -$19.2 million, and -$20.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | -31.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.13 Mn |
| Jun 30, 2026 | -31.13 Mn |
| Mar 31, 2026 | 171.34 Mn |
| Mar 31, 2026 | 171.34 Mn |
| Dec 31, 2025 | -19.23 Mn |
| Dec 31, 2025 | -19.23 Mn |
| Sep 30, 2025 | -20.21 Mn |
| Sep 30, 2025 | -20.21 Mn |
| Jun 30, 2025 | 40.87 Mn |
| Jun 30, 2025 | 40.87 Mn |
| Mar 31, 2025 | -21.82 Mn |
| Mar 31, 2025 | -21.82 Mn |
| Dec 31, 2024 | -22.89 Mn |
| Dec 31, 2024 | -22.89 Mn |
| Sep 30, 2024 | -20.85 Mn |
| Sep 30, 2024 | -20.85 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Mar 31, 2024 | 50.46 Mn |
| Mar 31, 2024 | 50.46 Mn |